Which peptides are studied for brain, nerve and sleep conditions?
Short answer
13 profiles here are grouped under “Brain, nerves and sleep”: 4 FDA-approved, 1 in clinical trials and 8 not FDA-approved.
Each entry below quotes its profile and links to the full answer there.
FDA-approved 4
Glatiramer acetate
Not a single peptide: a mixture often looked up alongside peptides
In clinical trials 1
Not FDA-approved 8
Cerebrolysin
Not a single peptide: a mixture often looked up alongside peptides
Not an FDA-approved drug14
Not FDA-approved. FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, epitalon acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.14,15,16
Not an FDA-approved drug18
Not FDA-approved. FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, Semax free base is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.15,16,18
Tesofensine
Not a peptide: a small molecule often looked up alongside peptides
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Drugs@FDA: COPAXONE (glatiramer acetate), NDA 020622 · original approval December 20, 1996 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 2COPAXONE (glatiramer acetate injection) · SPL version 36 · published 2026-06-26 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
- 3PITOCIN (oxytocin) injection · SPL version 15 · published 2026-05-21 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 4Drugs@FDA: PITOCIN (oxytocin), NDA 018261 · original approval November 19, 1980 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 5DAYBUE (trofinetide) solution; DAYBUE STIX (trofinetide) for solution · SPL version 12 · published 2026-09-11 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 6Drugs@FDA: DAYBUE (trofinetide), NDA 217026 · original approval March 10, 2023 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 7PRIALT (ziconotide acetate) injection, solution · SPL version 6 · published 2025-07-14 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 8Drugs@FDA application NDA021060 · original submission status AP · 2004-12-28 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 9Cibinetide (ARA 290) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 10Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 11Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (2017) · PMID 28475703 ↗
Investigative Ophthalmology & Visual Science · Official source · Source checked November 15, 2026
- 12Cerebrolysin substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 13FDA briefing document for emideltide (DSIP) (free base) and emideltide acetate ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
- 14FDA briefing document for epitalon ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 15Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 16HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 17Humanin substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 18FDA briefing document for Semax ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 19Tesofensine substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026